Search

everythinglearnresearchcommunity

for

Search:↓

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

A user created a web app called TrichoMetrics to track hair loss using photos and metrics like density and thinning. The app supports tracking treatments like Minoxidil and finasteride, with features for setting baselines, comparing progress, and logging treatment adherence.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

A 29-year-old male is experiencing positive hair regrowth after 3 months using oral finasteride (1mg) and topical minoxidil (1ml twice daily), despite side effects like scalp itchiness and dandruff. He plans to continue the treatment long-term and may switch to foam minoxidil to alleviate scalp issues.

A 34-year-old male documents his hair growth journey using the iRestore Elite laser cap, biotin, and Pure Synergy Organic Superfood Capsules, after unsuccessful hair transplant and previous treatments with minoxidil and finasteride. Replies suggest using finasteride or dutasteride instead and caution against excessive use of the laser cap.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

A user shared their 3-month progress using 1mg oral finasteride daily and applying topical minoxidil once daily, noting no side effects and darker hair. Another user praised the progress, anticipating even better results at the 6-month mark.

A 3 year journey of hair loss, with recession and diffuse thinning; the user has been taking finasteride for 3 years and is now switching to dutasteride and oral minoxidil, and may start using topical minoxidil soon.

A 43-year-old experienced hairline regrowth after 9 months using finasteride, oral and topical minoxidil, dermarolling, and vitamins. Users discussed the effectiveness and dosage of these treatments, with some expressing concerns about high doses and potential side effects.

Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

The user is using topical minoxidil 5% with 0.1% finasteride, ketoconazole shampoo, and a derma roller for hair regrowth. There is some progress, but it's hard to assess due to varying hair lengths.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The user experienced no improvement in hair loss with finasteride and minoxidil but had side effects. They plan to add wounding, scalp massage, vitamin K, and taurine supplements to their regimen and seek feedback on these additions.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

A thirty year old's progress with hair loss treatment, which includes finasteride, minoxidil and dermarolling in addition to taking multivitamins with biotin. The user has seen improvement after three months of using this regimen.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.

A user plans to create a custom topical solution by adding finasteride, caffeine, cetirizine, and melatonin to a minoxidil bottle, questioning the stability and effectiveness of this mix. Concerns include potential crystallization and solution muddiness with added ingredients.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The user reported progress in hair regrowth after three months of using oral finasteride and minoxidil foam, despite initial doubts. They noted no side effects, a clean diet, regular weightlifting, and additional supplements.